bpc-157 peptide explanation The “Wolverine” Drug – Ortho

For broader scientific reading on the compounds, researchers can explore peer-reviewed publications on PubMed BPC-157 and PubMed Thymosin Beta-4

Semaglutide Research# Semaglutide has one of the most comprehensive clinical evidence bases of any peptide: SUSTAIN trials (7 Phase 3 studies in T2D), STEP trials (4+ Phase 3 studies in obesity), SELECT trial (cardiovascular outcomes), and FLOW trial (kidney outcomes)

Originally used for diabetes management, its now widely recognized for its weight-loss benefits

It has been shown to increase peripheral glucose uptake (by ~13%), decrease hepatic gluconeogenesis (by ~20%) and reduce fasting plasma glucose levels